Skip to content

Applied Therapeutics, Inc.

CIK 0001697532

← back to feed
Revenue (TTM)
$1.19M
−95.4% YoY Q3 Nov 2025
Net Income (TTM)
−$146.08M
+11.8% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$1.10
+46.5% YoY Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
-7,266.7%
Q3 Nov 2025
Net Margin
-12,275.9%
Q3 Nov 2025
Free Cash Flow (TTM)
—
Q3 Nov 2025
Cash
$11.95M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
144.3M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings